Overview

Pattern Bioscience specializes in the rapid identification of bacterial infections and their antibiotic resistance profiles. Using advanced digital technology, the company combines single-cell analysis with AI pattern recognition to provide ID/AST results in just four hours, a significant reduction from traditional methods that can take days. The primary customers are hospitals and healthcare providers, including lab directors and infection prevention specialists. Pattern Bioscience differentiates itself by offering faster and more accurate diagnostics, which helps reduce unnecessary antibiotic prescriptions and addresses the global health issue of antibiotic resistance. The company's goal is to improve patient outcomes and combat antibiotic misuse in healthcare settings.

Simplify's Take

What believers are saying

• Rising antibiotic-resistant infections increase demand for rapid diagnostics like Pattern's.
• Global in vitro diagnostics market growth supports Pattern's product demand.
• FDA's focus on diagnostic tool approval could expedite Pattern's market entry.

What critics are saying

• Competition from companies like Accelerate Diagnostics may impact Pattern's market share.
• Regulatory hurdles could delay FDA approval and affect revenue.
• AI-driven analysis tools may face biases, impacting diagnostic accuracy.

What makes Pattern Bioscience unique

• Pattern Bioscience uses patented phenotypic single-cell technology for pathogen identification.
• Their Digital CultureTM technology offers comprehensive resistance mechanism analysis.
• AI pattern recognition enables rapid, accurate ID/AST results in just four hours.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$48.6M

Below

Industry Average

Funded Over

4 Rounds

$28,700,000

Series C

Apr 2023

Series C funding is usually for startups that are doing well and are looking for more money to fuel major growth, such as acquiring other companies, expanding into global markets, or launching new product lines. Investors typically include larger venture capital firms and private equity.

Series C Funding Comparison

Below Average

Industry standards

Ind Avg. $50M

$16M

$28.7M

$40M

$50M

$62M

$100M

View all funding stages